Onset dynamics of type A botulinum neurotoxin-induced paralysis
暂无分享,去创建一个
Frank J. Lebeda | Yaroslav Chushak | F. Lebeda | M. Adler | Y. Chushak | Michael Adler | Keith Erickson | Keith Erickson
[1] J. Keller. Recovery from botulinum neurotoxin poisoning in vivo , 2006, Neuroscience.
[2] F. Lebeda,et al. Membrane Channel activity and Translocation of Tetanus and Botulinum Neurotoxins , 1999 .
[3] R. S. Williams,et al. Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes. , 1982, Toxicon : official journal of the International Society on Toxinology.
[4] L. Simpson. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. , 1980, The Journal of pharmacology and experimental therapeutics.
[5] M. Geeves. Kinetics of fast enzyme reactions: Theory and practice , 1980 .
[6] C. Permpikul,et al. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Richard D. O'Brien,et al. The Receptors : a comprehensive treatise , 1979 .
[8] Eric A. Johnson,et al. SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.
[9] J. Dolly,et al. Productive and non‐productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain , 1996, Journal of neuroscience research.
[10] J. Romano,et al. Chemical Warfare Agents : Toxicity at Low Levels , 2000 .
[11] Philip K. Russell,et al. Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.
[12] B. Davletov,et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves , 2006, FEBS Letters.
[13] F. Lebeda,et al. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. , 1995, Toxicon : official journal of the International Society on Toxinology.
[14] L. Simpson,et al. Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.
[15] C. Schengrund,et al. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. , 2001, Toxicon : official journal of the International Society on Toxinology.
[16] G. Oyler,et al. Pharmacological Countermeasures for Botulinum Intoxication , 2000 .
[17] E. Albuquerque,et al. Kinetic analysis of end plate currents altered by atropine and scopolamine. , 1978, Molecular pharmacology.
[18] Hiroaki Kitano,et al. Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. , 2003, Omics : a journal of integrative biology.
[19] J. McLauchlin,et al. An outbreak of serious illness and death among injecting drug users in England during 2000. , 2002, Journal of medical microbiology.
[20] D. Dressler,et al. Botulinum Toxin: Mechanisms of Action , 2005, European Neurology.
[21] T. Lohman,et al. Review of Wyman and Gill, Binding and Linkage: Functional Chemistry of Biological Macromolecules , 1993 .
[22] J. Dolly,et al. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation , 2003, Molecular and Cellular Neuroscience.
[23] J. Marks. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization , 2004, Movement disorders : official journal of the Movement Disorder Society.
[24] L. Simpson. Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. , 1974, Neuropharmacology.
[25] C. Millard,et al. Medical Defense Against Protein Toxin Weapons , 2005 .
[26] G. Schiavo,et al. Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.
[27] K. Bostian,et al. Endoproteinase Activity of Type A Botulinum Neurotoxin: Substrate Requirements and Activation by Serum Albumin , 1997, Journal of protein chemistry.
[28] P. Savino,et al. Botulinum toxin therapy. , 1991, Neurologic clinics.
[29] C. Schengrund,et al. Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. , 2004, Biochemistry.
[30] E. Otten. Chemical Warfare Agents: Toxicity at Low Levels , 2002 .
[31] J. Hablitz,et al. Role of uptake inγ-aminobutyric acid (GABA)-mediated responses in guinea pig hippocampal neurons , 1985, Cellular and Molecular Neurobiology.
[32] S. Joshi,et al. An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin , 2006, Journal of Pharmacology and Experimental Therapeutics.
[33] K. Roger Aoki. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. , 2002, Toxicon : official journal of the International Society on Toxinology.
[34] D. Truong. Botulinum Toxin Therapy , 1991, The Western journal of medicine.
[35] D. Rodbard,et al. Kinetics of Cooperative Binding , 1979 .
[36] K. Aoki. Botulinum toxin: a successful therapeutic protein. , 2004, Current medicinal chemistry.
[37] H. Gutfreund,et al. Enzyme kinetics , 1975, Nature.
[38] Eric A. Johnson,et al. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. , 2001, Toxicon : official journal of the International Society on Toxinology.
[39] J. Coffield,et al. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. , 2001, The Journal of pharmacology and experimental therapeutics.
[40] M. Montal,et al. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel , 2003, Nature Structural Biology.
[41] H. Bigalke,et al. The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction , 2003, Molecular microbiology.
[42] C. Frassoni,et al. Entering neurons: botulinum toxins and synaptic vesicle recycling , 2006, EMBO reports.